Research Article

Liver transplantation for hepatocellular carcinoma: Lessons learned from six years of experience

Volume: 59 Number: 4 December 30, 2020
EN TR

Liver transplantation for hepatocellular carcinoma: Lessons learned from six years of experience

Abstract

Aim: Liver transplantation (LT) remains the best treatment option for hepatocellular carcinoma (HCC). Patient selection is crucial and debated ever since the emerging of the Milan criteria in 1996. As live donor LT being more routinely performed worldwide, numerous new and/or expansions of the original criteria have been suggested to allow more patients to benefit from this superior treatment modality. This study aims to contribute to ever-growing data in search for better coverage of patients with acceptable outcomes. Materials and Methods: Medical recordings of 187 adult patients who underwent LT for HCC in a 6-year period were retrospectively collected. Patients were classified by Milan and UCSF criteria. Survival times as well as tumor, liver disease and recurrence related data were recorded for each patient and the outcomes were statistically analyzed. Results: Factors significantly affecting recurrence and survival were histologic differentiation, number and the size of the tumor and the presence of vascular invasion. Serum alpha-fetoprotein levels did not significantly affect outcomes. Among the patients exceeding both of the criteria, having a total tumor size of less than 160 mm was significantly associated with better outcomes (p=0,007). Conclusion: In conclusion, HCC patients having tumors with vascular invasion, poor differentiation, exceeding 6 in number and 160 mm in total diameter demonstrate higher recurrence rates and worse outcomes.

Keywords

References

  1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13.
  2. Lee HW, Suh K-S. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016 Apr;21(2):231–7.
  3. Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer. 2012 Nov;1(3–4):144–58.
  4. Gunay Y, Guler N, Yaprak O, Dayangac M, Akyildiz M, Altaca G, et al. Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria. Indian J Surg. 2015 Dec;77(Suppl 3):950–6.
  5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35–43.
  6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693–9.
  7. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993 Aug;218(2):145–51.
  8. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991 Sep;214(3):221–8; discussion 228-229.

Details

Primary Language

Turkish

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Cahit Yılmaz
0000-0001-6401-0767
Türkiye

Publication Date

December 30, 2020

Submission Date

March 30, 2020

Acceptance Date

July 9, 2020

Published in Issue

Year 1970 Volume: 59 Number: 4

Vancouver
1.Can Karaca, Cahit Yılmaz. Hepatoselüler kanser için karaciğer nakli: Altı yıllık deneyimin öğrettikleri. EJM. 2020 Dec. 1;59(4):265-71. doi:10.19161/etd.834132

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.